Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis
Zeidan A, Hu X, Zhu W, Stahl M, Giri S, Huntington S, Wang R, Podoltsev N, Gore S, Ma X, Davidoff A. Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis. Blood 2018, 132: 370. DOI: 10.1182/blood-2018-99-111052.Peer-Reviewed Original ResearchHMA cyclesOverall survivalHMA initiationHMA therapyMyelodysplastic syndromeProvider typeCancer CenterMD volumeMultivariate Cox proportional hazardsKaplan-Meier log-rank testAZA-001 trialMedian overall survivalTwo-sided statistical testsLog-rank testReal-world survivalCox proportional hazardsLogistic regression analysisWilcoxon rank sum testChi-square testCommunity-based practiceRank sum testEligible ptsLookback periodEarly discontinuationAgent therapyRandomized Trial of the Impact of Empowering Childhood Cancer Survivors With Survivorship Care Plans
Kadan-Lottick NS, Ross WL, Mitchell HR, Rotatori J, Gross CP, Ma X. Randomized Trial of the Impact of Empowering Childhood Cancer Survivors With Survivorship Care Plans. Journal Of The National Cancer Institute 2018, 110: 1352-1359. PMID: 29771337, DOI: 10.1093/jnci/djy057.Peer-Reviewed Original ResearchConceptsSurvivorship care plansChildhood cancer survivorsPrimary care physiciansLate complicationsCancer survivorsSurvivorship clinicCare plansSC groupNew late complicationSurveillance testsTwo-sided statistical testsHealth care quality measuresAge 18 yearsCare quality measuresClinic attendanceCare physiciansPatient adherenceTreatment summaryTherapy surveillanceComplicationsAssignment groupCancer diagnosisAdherenceSurvivorsTrials